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$2205 for salmeterol, $1911 for montelukast) in year 2.
There were no signiﬁcant differences in the adjusted
asthma-related health care costs and utilization. Although
the montelukast group showed higher compliance in the
bivariate analysis, this was not signiﬁcant in the multi-
variate regression. Overall ICS use decreased by 16% in
year 2 (p < 0.01), but there were no differences between
the two groups with regard to relative reduction of ICS
reﬁlls.
CONCLUSIONS: Adding either montelukast or salme-
terol as additional controller to ICS therapy was not 
associated with changes in either health care service 
utilization or costs in Medicaid-enrolled asthmatic
patients. However, their addition was associated with a
decrease in inhaled corticosteroid use, suggesting
decreased compliance in patients on the 2-drug regimen.
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RESOURCE UTILIZATION FOR INPATIENT
ASTHMA CARE IN CHILDREN AND ADULTS:AN
ANALYSIS OF HCUP DATA
Hassan MK,Amonkar MM
West Virginia University, Morgantown, WV, USA
OBJECTIVES: To estimate differences in length of stay
(LOS), emergency room (ER) visits and charges for 
inpatient asthma care between children and adults based
on insurance coverage, patient and hospital-based 
characteristics.
METHODS: The 1997 Nationwide Inpatient Sample of
the Healthcare Cost and Utilization Project data were
used to extract 183,400 childhood (age <17 years) and
251,760 adult asthma cases (primary diagnosis using
ICD-9 codes 493.00–493.91). Two-way ANOVA was
conducted to determine differences in LOS and total
charges between adult and childhood asthma based on
type of insurance coverage (Medicaid, private insur-
ance/HMO and self-pay) while chi-square analysis was
conducted to detect differences based on number of ER
visits. Regression models were developed separately for
childhood and adult asthma to examine if LOS and total
charges (multiple regression) and ER visits (logistic
regression) are affected by patient-related (race, gender,
number of co-morbidities and insurance status) and 
hospital-related (bed-size, location, teaching and 
ownership status) factors.
RESULTS: Overall, average length of stay for childhood
and adult asthma was 2.43 days and 3.98 days, respec-
tively. Mean total charges for childhood asthma was
$4,532 as compared to $7,713 for adult asthma. Almost
70% of adult asthmatics had ER visits as compared to
62% of asthmatic children. Adults had signiﬁcantly
higher total charges, LOS and ER visits for all types of
payers as compared to children. Medicaid-eligible adults
and children showed highest hospitalization charges, LOS
and ER visits. Non-whites, patients with higher number
of co-morbidities, urban and teaching hospitals were
associated with higher charges, LOS and ER visits, for
both adult and childhood asthma.
CONCLUSIONS: Adult asthmatics, especially Medicaid
beneﬁciaries, have higher inpatient charges, LOS and ER
visits as compared to asthmatic children. Future studies
should be aimed at reducing asthma-related ER visits and
investigating variations in resource utilization based 
on insurance coverage and patient and hospital-related
characteristics.
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SODIUM NEDOCROMIL
Prosekova E1, Geltzer B1, Dercach V2, Bogdanovskiy P1,
Frisman M1
1Vladivostok State Medical University,Vladivostok, Russia;
2Child’s Municipal Asthma-centre,Vladivostok, Russia
OBJECTIVES: Comparative estimation cost and 
inﬂuence on quality of life in children with middle severe
asthma sodium cromoglycate and sodium nedocromil.
METHODS: Cost-utility analysis was conducted in
Child’s Municipal Asthma-Centre during 1998–2000
years in 100 children with asthma. We determined one
year expenses for quality adjusted life years (QALY). For
estimation quality of life we used “Childhood question-
naire” by A. West, D. French adapted for Russian by 
V. Petrov and I. Smolenov and index Rosser-Kind. 
Estimation of expenditures included direct and indirect
expenses.
RESULTS: The investigation revealed the differences in
therapeutic effectiveness and quality of life depending on
treatment method. Using therapy by nedocromil sodium
during one year, the total sum of positive effect on quality
of children’s life was 149,8%; health index 0,985 and
expenses on drug—3672,3 ± 40,4 roubles. Using 
sodium cromoglycate these indices were 70,9%; 0,965
and 1862,4 ± 24,2 roubles accordingly. Annual cost of
middle severe asthma for one child was 5051,4 ± 68,6
roubles using sodium nedocromil (72,7% expenditures
formed expenses on the drug); using sodium cromogly-
cate—5044,7 ± 110,4 roubles (36,92%) accordingly. In
the second case expenses on QALY were much more—
5207,65 in consequence of expenses on hospital care and
additional therapy.
CONCLUSIONS: Therapy by sodium cromoglycate of
middle severe asthma didn’t provide complete disease
control. In this case necessity in additional therapy for
improvement quality of life is increased.
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OBJECTIVE: To examine determinates of asthma cost in
a large employer population.
METHODS: Data was drawn from the MedStat 
database. Medstat is a claims-based database with over 5
million members. Individuals were identiﬁed as asthmat-
ics based on either a hospitalization, emergency room
(ER) or outpatient visit with a primary diagnosis of
asthma. Final sample size was 107,432.
RESULTS: Overall mean expenditures for inpatient, 
outpatient and emergency room care were $417, the
majority attributable to outpatient care ($270). Both ER
visits (2.6% of the sample) and inpatient stays (2.5%)
were relatively infrequent. But, among ER users, mean ER
expenditures ($438) were greater than total mean expen-
ditures for the typical asthmatic. Similarly, mean hospital
expenditures for those using inpatient services were large
($5,316). ER visits were most likely for those aged 18–34
and became more infrequent with age. Conversely, 
hospital stays were least frequent for those 18–34 and 
otherwise showed no age trend. Although the frequency
of inpatient events didn’t increase with age, the cost was
positively correlated with age, with the lowest mean 
inpatient expenditures for the 18–34 age group ($98) and
the highest for those age 65 and over ($355). Outpatient
costs showed a similar trend, with the highest costs for
those over 65 ($355) and the lowest for the 0–18 age
group ($237). Overall costs in the over 65 age group
($589) were signiﬁcantly greater than the lowest cost
group, ages 18–34 ($375). Mean total costs for women
($446) were higher than for men ($379), largely due to
higher outpatient costs. Women more frequently used
inpatient services (2.7% versus 2.4%), but were less likely
to use the ER (2.5% versus 2.9%).
CONCLUSIONS: Asthma is a high cost chronic illness in
employer populations. Strategies to identify and manage
high cost individuals may lead to cost savings.
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OBJECTIVES: To develop a model of the cost of treat-
ment of asthma for planning and evaluation purposes.
METHODS: The model is based on the ﬁve states classi-
ﬁcation of the GIA (Global Initiative on Asthma) A 
preliminary model was designed and validated by a group
of expert clinicians, which deﬁned also the current treat-
ment patterns. On the basis of that information a tem-
plate was designed for the collection of the following
data: visits, in-patient stays, lab tests, drug treatments and
clinical state. Retrospective data were collected for 3 and
5 years from 36 clinical records of 6 outpatient units of
6 Catalan hospitals. The cost at each state as well as the
probabilities of transition between states was derived
from the former data.
RESULTS: The average annual cost at 1997 prices is
US$250. The distribution by resource category is: visits
33.5%, in-patient care 9.3%, lab tests 13.6% and drugs
43.6%. The cost in the ﬁrst year is twice as much as the
average of the following years. There are no signiﬁcant
differences in cost between pediatric and adult patients.
The three years treatment cost does not seem to have
increased over time between the patients starting 
treatment in 1996 and those starting in 1998. The 
initial simulation model gave an annual treatment cost of
US$215, 250 and 285, respectively, for patients being in
states one, two or three at the ﬁrst visit.
CONCLUSIONS: The model reﬂects physicians under-
standing of the disease process and can be easily popu-
lated with data from clinical records. Given the limited
size of the sample, transition probabilities were assumed
to depend only from the previous state, but not from the
state at the ﬁrst visit or from other patient characteristics.
These simplifying assumptions could and should be
relaxed if data from a larger sample were available.
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USE DATA COLLECTION
O’Brien J, Lordan N,Ward A
Caro Research Institute, Concord, MA, USA
OBJECTIVES: Compliance is a concern when trying to
capture resource use (RU) data over a long period. An
IVRS was developed to capture RU data for chronic
obstructive pulmonary disease and to assess the viability
of using a patient-oriented IVRS system for periodic and
long-term RU data collection. This presentation will focus
on results of the second objective.
METHODS: This study was done over 58 weeks in 
parallel with a clinical trial. At the initial study visit, 
subjects were instructed in the use of the IVRS, provided
written instructions and a Health Care Resource Use
Tracking Aid© for each of 14 reporting periods. Subjects
were instructed to record RU daily on the tracking aid
and to report via the IVRS toll-free number each 30 days
during the course of the study. IVRS data were accessed
weekly for data monitoring. Reminders were generated
to patients who did not complete a scheduled report. Two
RU reporting periods extended beyond the last clinical
trial visit. Subjects resided in 23 states.
RESULTS: Males comprised 58% of study subjects; 55%
were greater than 65 years old; and 53% resided in
Southern states. All 381 IVRS users reported resource use
data at least once. The average number of IVRS reports
per subject was 10.5 (sd = 4.5). Of those subjects who
ﬁnished the trial, 89% completed at least 12, and 46%
completed all 14 data reports.
CONCLUSIONS: This study demonstrated that multiple
data reporting via an IVRS can be used successfully for
collecting long-term health care resource use data even
when a substantial portion of the subjects are elderly. The
